Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Systemic AMG 108 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Minor sub-study AMG 108 | ACTIVE_COMPARATOR | N = 15 |
| Minor sub-study placebo | PLACEBO_COMPARATOR | N = 15 |
| Main sub-study AMG 108 | ACTIVE_COMPARATOR | N = 73 |
| Main sub-study placebo | PLACEBO_COMPARATOR | N = 73 |
| Name | Type | Description |
|---|---|---|
| Systemic AMG 108 | DRUG | 300 mg SC AMG 108 Q4W for 3 doses |
| Placebo | OTHER | SC placebo injection Q4W for 3 doses |
Inclusion Criteria: * Diagnosed with knee OA as determined by American College of Rheumatology (ACR) criteria * Pain defined by a level of greater than or equal to 30 mm on a 100 mm Visual Analogue Scale (VAS) * If currently taking any over the counter nutritional supplements, must be on stable dos...
AMG 108 is an investigational small molecule being developed for the treatment of osteoarthritis, a degenerative joint disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AMG 108 is being developed by Amgen Inc., a biotechnology company listed on NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical trials for osteoarthritis.
AMG 108 is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. A Phase 2 clinical trial for osteoarthritis has been completed.
AMG 108 has one completed Phase 2 clinical trial, identified as NCT00110942, titled "Treatment for Patients With Osteoarthritis (OA)." The trial enrolled 160 participants aged 30 years and older with osteoarthritis.
AMG 108 is the drug name used in clinical trials for this investigational treatment. No alternative names have been reported for this compound in the available clinical trial information.